Cristal Therapeutics awarded €2.5 million Horizon 2020 grant to advance its CriPec®-docetaxel through Phase 2 trials

/in /by

Maastricht, The Netherlands, 28 November 2017 – Cristal Therapeutics, a clinical stage biopharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need, today announced that it secured a €2.5 million grant from the European Commission’s Horizon 2020 programme. The funds will be used to perform the upcoming […]

Read more

Cristal Therapeutics progresses nanomedicine CriPec®-docetaxel to phase 1b development in patients with solid tumours

/in /by

Maastricht, The Netherlands, 1 November 2017 – Cristal Therapeutics, a clinical stage biopharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need, announced today that it has begun a Phase 1b clinical program of its lead nanomedicine candidate CriPec®-docetaxel in patients with solid tumours. This CriPec®-docetaxel program will […]

Read more

Dr. Istvan Udvaros joins Cristal Therapeutics as New Chief Medical Officer

/in /by

Maastricht, The Netherlands, 24 October 2017 – Cristal Therapeutics, a clinical stage biopharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need, has appointed Dr. Istvan Udvaros as its Chief Medical Officer (CMO) with immediate effect. He will be responsible for the clinical strategy and development of […]

Read more

Cristal Therapeutics further strengthens its Scientific Advisory Board with appointment of Dr. Paul Lammers

/in /by

Cristal Therapeutics Further Strengthens its Scientific Advisory Board with Appointment of Dr Paul Lammers Maastricht, The Netherlands, August 9, 2017 – Cristal Therapeutics, a clinical stage biopharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need, today announced the appointment of Dr Paul Lammers to its Scientific […]

Read more

Cristal Therapeutics raises €12.8 million in new financing round to advance novel medicines against cancer using its CriPec® nanotech platform

/in /by

Cristal Therapeutics raises €12.8 million in new financing round to advance novel medicines against cancer using its CriPec® nanotech platform Round led by Aglaia BioMedical Ventures and DROIA Oncology Ventures Funding used: to execute clinical phase Ib and phase IIa trials with CriPec® docetaxel to further leverage the CriPec® platform for oligonucleotides programs from proof […]

Read more